Sheffield-based aquaculture biotech firm Benchmark Holdings said on Tuesday its revenue from continuing operations rose 6% to £59.5 million in the six months to March 31, 2021, and loss before tax from continuing operations narrowed to £3.3 million from £13.4 million.
Benchmark’s portfolio of products includes salmon eggs with specialist genetic traits, shrimp broodstock, tilapia fry, technology enhanced live feed, specialist diets, probiotics and sea lice treatments.
Benchmark CEO Trond Williksen said: “Benchmark has performed well in the first half and has made good strategic progress across our three business areas.
“This reflects our successful restructuring and the new focus and discipline on delivering on our strategic priorities to create profitable growth.
“Our financial discipline including cost containment and strict cash management enables us to invest selectively in our core business, strengthen our position in our markets and deliver on the growth opportunities ahead.
“As a leading aquaculture biotechnology company focused on delivering sustainable solutions, we are well positioned to make a positive impact on our industry and create value for all our stakeholders.”